Physician profile
Josh J Weng
NPI 1043219678
$15,508.91
in general payments reported to CMS, 2019-2025
52 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,139 · 2020: $1,966 · 2021: $1,693 · 2022: $2,379 · 2023: $1,958 · 2024: $1,971 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Travel and Lodging: $13.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.28 |
| Travel and Lodging | $13.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,198.66 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,670.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,512.34 | 2019-2025 | Linzess, Creon, Viberzi |
| Radius Health, INC. | $1,277.05 | 2019-2025 | Tymlos |
| Gilead Sciences, INC. | $934.97 | 2019-2025 | |
| Lilly USA, LLC | $908.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $666.55 | 2019-2025 | |
| Amarin Pharma, INC. | $641.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $641.50 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $608.76 | 2022-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $468.52 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $457.21 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $425.23 | 2021-2025 | Verquvo, Belsomra, Januvia |
| Almatica Pharma LLC | $418.28 | 2022-2024 | Loreev Xr, Teriparatide, Gralise |
| Glaxosmithkline, LLC. | $272.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.